


LH21

Cat. No.:	HY-121827		
CAS No.:	611207-11-5		
Molecular Formula:	C ₂₀ H ₂₀ Cl ₃ N ₃		
Molecular Weight:	408.75		
Target:	Cannabinoid Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (244.65 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.4465 mL	12.2324 mL	24.4648 mL
5 mM	0.4893 mL	2.4465 mL	4.8930 mL
10 mM	0.2446 mL	1.2232 mL	2.4465 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: 5 mg/mL (12.23 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 5 mg/mL (12.23 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats., and displays efficacy as a feeding inhibitor^[1].

REFERENCES

- [1]. Francisco Javier Pavon, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21. *Neuropharmacology*

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA